^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FPI-2265

    i
    Other names: FPI-2265, Ac225-PSMA I&T, 225Actinium-PSMA-I&T
    Associations

    News

    Trials
    Company:
    Fusion Pharma
    Drug class:
    α radiation emission, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (clinicaltrials.gov)
    P2, N=115, Recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    FPI-2265
    1year
    Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). (clinicaltrials.gov)
    P2, N=100, Recruiting, Excel Diagnostics and Nuclear Oncology Center | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date
    |
    MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    FPI-2265